Blog
RSS FeedPosted by Michael Wonder on 09 Oct 2018
Evidence-based approach to funding choices more important than ever
10 October 2018 - Cancer will affect almost all New Zealanders at some point in their lives. Given the range ...
Posted by Michael Wonder on 09 Oct 2018
Outdated public funding model failing New Zealand patients
9 October 2018 - Publicly funded modern medicines are out of reach for many patients in New Zealand according to ...
Posted by Michael Wonder on 08 Oct 2018
Who knows the true cost of medicines?
1 October 2018 - PHARMAC director of operations Lisa Williams says the drug-buying system delivers good value for Kiwis, even though ...
Posted by Michael Wonder on 08 Oct 2018
The high cost of living for advanced breast cancer patients
6 October 2018 - Donna MacMillan: ''I feel as if the Government doesn't care whether I live or die. That I ...
Posted by Michael Wonder on 08 Oct 2018
Family pleads with PHARMAC to help save toddler's life by funding cystic fibrosis ‘wonder drug’
8 October 2018 - Sixteen-month-old Otis Porter's parents are pleading for Kalydeco to be funded, to help the toddler live. ...
Posted by Michael Wonder on 01 Oct 2018
PHARMAC must fund breakthrough treatment
1 October 2018 - Cystic Fibrosis NZ and Kalydeco for Kiwis have launched a joint campaign urging PHARMAC to fund ...
Posted by Michael Wonder on 29 Sep 2018
New Zealand Pharmaceutical Schedule - 1 October 2018 update
1 October 2018 - The October 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Sep 2018
Decision to fund sapropterin
28 September 2018 - PHARMAC is pleased to announce a decision to list sapropterin (Kuvan), a treatment for the rare ...
Posted by Michael Wonder on 26 Sep 2018
PHARMAC urged to subsidise cost prohibitive but 'highly effective' contraceptive option
26 September 2018 - The Mirena is a popular and effective contraceptive option but it's $340 price tag has been ...
Posted by Michael Wonder on 25 Sep 2018
Decision to change the funded brand of epoetin alfa
24 September 2018 - PHARMAC is pleased to announce the approval of an agreement with Novartis for the supply of ...
Posted by Michael Wonder on 13 Sep 2018
PHARMAC defends position not to fund bowel cancer drug
14 September 2018 - PHARMAC is defending its position to not fund a drug recommended to patients with late-stage bowel cancer ...
Posted by Michael Wonder on 13 Sep 2018
Dying cancer patients refused PHARMAC funding
13 September 2018 - Dying patients who suffer a rare reaction to chemotherapy are having to pay for their own ...
Posted by Michael Wonder on 12 Sep 2018
Decision to list nintedanib (Ofev) and remove restrictions from tiotropium bromide (Spiriva)
12 September 2018 - PHARMAC is pleased to announce a decision to list nintedanib (Ofev) and remove the current Special ...
Posted by Michael Wonder on 06 Sep 2018
Proposal on the funding of infliximab, rituximab and tocilizumab
6 September 2018 - PHARMAC is proposing to change how three hospital medicines are managed within the Pharmaceutical Schedule. ...
Posted by Michael Wonder on 06 Sep 2018
Approval of multi-product funding agreement with Novartis
6 September 2018 - PHARMAC is pleased to announce a major funding package involving ten medicines in seven key therapy ...